Passer au contenu principal

Calcium pyrophosphate deposition

Pseudogout

Professionnels de la santé

Les articles de référence professionnelle sont conçus pour être utilisés par les professionnels de la santé. Ils sont rédigés par des médecins britanniques et basés sur des preuves de recherche, des directives britanniques et européennes. Vous pouvez trouver le Calcium pyrophosphate deposition article plus utile, ou l'un de nos autres articles de santé.

Contexte12

Previously known as pseudogout, calcium pyrophosphate deposition disease (CPPD) is an inflammation of joints caused by the deposition of calcium pyrophosphate (CPP) crystals in articular and periarticular tissues.

Épidémiologie34

  • Calcium pyrophosphate deposition is common in the elderly. Half of adults develop radiographic changes typical of CPPD by the age of 80.

  • 30-50% of patients with CPPD are over the age of 85.4

  • Most cases of CPPD are non-familial but mutations in the ANK human gene (ANKH) have been demonstrated in some families.5

  • Due to the low sensitivity of conventional radiography, it is likely that the prevalence of CPPD is underestimated.

CPPD is associated with:467

  • Déshydratation.

  • Intercurrent illness.

  • Previous surgery or trauma to the joint.

  • A history of gout.

  • Family history of CPPD.

  • Arthrose.

  • Primary hyperparathyroidism.

  • Hémochromatose.

  • Hypophosphatasia.

  • Hypomagnesaemia.

Présentation34

CPPD is often asymptomatic, with only radiographic changes of chondrocalcinosis.

Calcium pyrophosphate deposition may cause an acute or chronic arthritis:

Acute CPP crystal arthritis (or pseudogout):

  • Acute onset of monoarticular or oligoarticular arthritis.

  • The knee is the most commonly involved joint, followed by the wrist.

  • Acute attacks of CPPD disease usually settle within 10 days but may last for weeks or months.

  • Systemic symptoms including fevers, and chills, and constitutional symptoms may occur.

Chronic CPP crystal arthritis:

  • Most affected patients have a polyarticular form of arthritis that resembles osteoarthritis, but with flares of inflammatory signs and symptoms and by unusually severe articular damage. Involvement of joints such as the glenohumeral joint, wrist, and metacarpophalangeal joints, which are not often affected by typical osteoarthritis, should lead one to suspect CPPD disease.

  • A rarer form of polyarticular CPPD disease resembles rheumatoid arthritis, with persistent inflammatory arthritis that affects large and small joints. Flares often involve joints sequentially, and involvement is less symmetric than that seen with rheumatoid arthritis.

Diagnostic différentiel

Enquêtes38

  • Plain x-ray, ultrasound, CT scan and DECT scans can all be used in the diagnosis of CPPD.

  • Crystals can be identified on aspiration of the joint fluid.

Gestion8910 11

Unlike gout, there are no specific disease-modifying treatments for the elimination of CPP crystals from the body. Treatment is therefore largely symptomatic, as well as ensuring good management of any underlying metabolic conditions. Care should be tailored to individual patients and should take account of any comorbidities and existing medication regimes.

The European guidelines advice the use of non-steroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids (intra-articular or systemic). The drug of choice will depend on the patient's age and comorbidities.

In 2023, a large study supported the use of prednisolone 30 mg a day as the first line treatment for CPPD. If colchicine is used, initiation in the first 12 hours of symptoms is important.

For chronic CPP crystal arthritis:

  • Daily colchicine is the preferred first-line treatment, whereas methotrexate and tocilizumab are considered second-line options.47

  • For patients with monoarticular or oligoarticular large-joint involvement, repeated intra-articular injections of glucocorticoids may control symptoms.

Pronostic4

  • Acute attacks often resolve within ten days.

  • However some acute attacks may last for weeks or months.

  • Some patients develop progressive joint damage with functional limitation.

  • Chronic CPPD is characterised by recurrent flare-ups, with symptoms that frequently overlap those of rheumatoid arthritis.

  • Prognosis will also be dependent on any underlying cause.

Mises à jour exclusives pour les professionnels de la santé

Restez informé des dernières mises à jour cliniques, des perspectives professionnelles et des conseils fondés sur des preuves. La newsletter Patient Pro sélectionne des contenus essentiels pour les professionnels de santé—livrés directement dans votre boîte de réception.

Veuillez entrer une adresse e-mail valide

En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.

Lectures complémentaires et références

  1. Rosenthal AK, Ryan LM; Calcium Pyrophosphate Deposition Disease. N Engl J Med. 2016 Jun 30;374(26):2575-84. doi: 10.1056/NEJMra1511117.
  2. Pseudogout, chondrocalcinosis, CPPD et al: crystal clear… or clear as mud?–The time has come to reconsider the nomenclature of calcium pyrophosphate deposition; S Sirotti et al; Annals of the Rheumatic Diseases
  3. EULAR recommendations for calcium pyrophosphate deposition - Part I: terminology and diagnosis; European League Against Rheumatism (2011)
  4. Azam A, Minalyan A, Naik R; Calcium Pyrophosphate Deposition Disease.
  5. Tsui FW; Genetics and mechanisms of crystal deposition in calcium pyrophosphate deposition disease. Curr Rheumatol Rep. 2012 Apr;14(2):155-60. doi: 10.1007/s11926-011-0230-6.
  6. Calcium pyrophosphate deposition disease: The arthropathy formerly known as “Pseudogout”; BPAC NZ
  7. Calcium pyrophosphate deposition disease; Prof T Pascar et al; The Lancet
  8. Calcium pyrophosphate dihydrate deposition disease; R Sharma; Radiopedia
  9. EULAR recommendations for calcium pyrophosphate deposition - Part II Management; European League Against Rheumatism (2011)
  10. Recent advances in the therapeutic management of calcium pyrophosphate deposition disease; P Voulgari et al; Frontiers in Medicine
  11. Diagnosis and Treatment of Calcium Pyrophosphate Deposition (CPPD) Disease: A Review; S Cowley and G McCarthy; Open Access Rheumatology: Research and Reviews

Historique de l'article

Les informations sur cette page sont rédigées et examinées par des cliniciens qualifiés.

Pharmacie en ligne, traitements et services de santé

Accès simple à des traitements fiables et à des services de santé en ligne.

Common conditions

Get help with common conditions through the NHS, without a GP appointment.

Book your free Pharmacy First appointment